UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 381

Sortiert nach

Intrusive social support among Black and White individuals with type 2 diabetes: A "Control issue" or a sign of "Concern and love"?

PloS one, 2023-08, Vol.18 (8), p.e0288258-e0288258

2023

Link zum Volltext

Verfügbarkeit prüfen

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

The AAPS journal, 2022-01, Vol.24 (1), p.19-19, Article 19

2022

Link zum Volltext

Verfügbarkeit prüfen

BEATS: Bayesian hybrid design with flexible sample size adaptation for time‐to‐event endpoints

Statistics in medicine, 2023-12, Vol.42 (30), p.5708-5722

2023

Link zum Volltext

Verfügbarkeit prüfen

Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN‐ET

Pharmaceutical statistics : the journal of the pharmaceutical industry, 2023-05, Vol.22 (3), p.440-460

2023

Link zum Volltext

Verfügbarkeit prüfen

Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Contemporary clinical trials, 2020-09, Vol.96, p.106083-106083, Article 106083

2020

Link zum Volltext

Verfügbarkeit prüfen

DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior

Journal of biopharmaceutical statistics, 2024-03, p.1-18

2024

Link zum Volltext

Verfügbarkeit prüfen

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

Statistics in medicine, 2024-05, Vol.43 (12), p.2439-2451

2024

Link zum Volltext

Verfügbarkeit prüfen

Flexible seamless 2-in-1 design with sample size adaptation

Journal of biopharmaceutical statistics, 2024-03, p.1-19

2024

Link zum Volltext

Verfügbarkeit prüfen

Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18896-e18896

2023

Link zum Volltext

Verfügbarkeit prüfen

Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18891-e18891

2023

Link zum Volltext

Verfügbarkeit prüfen

Quantitative Translation in Immuno‐Oncology Research and Development

Clinical pharmacology and therapeutics, 2020-09, Vol.108 (3), p.430-433

2020

Link zum Volltext

Verfügbarkeit prüfen

PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints

Journal of biopharmaceutical statistics, 2022-07, Vol.32 (4), p.567-581

2022

Link zum Volltext

Verfügbarkeit prüfen

Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata

Journal of biopharmaceutical statistics, 2020-09, Vol.30 (5), p.806-820

2020

Link zum Volltext

Verfügbarkeit prüfen

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

The New England journal of medicine, 2018-01, Vol.378 (4), p.331-344

2018

Link zum Volltext

Verfügbarkeit prüfen

TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy

Journal of biopharmaceutical statistics, 2020-11, Vol.30 (6), p.979-992

2020

Link zum Volltext

Verfügbarkeit prüfen

Flexible Bayesian subgroup analysis in early and confirmatory trials

Contemporary clinical trials, 2020-11, Vol.98, p.106149-106149, Article 106149

2020

Link zum Volltext

Verfügbarkeit prüfen

Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials

Statistics in biopharmaceutical research, 2019-10, Vol.11 (4), p.407-418

2019

Link zum Volltext

Verfügbarkeit prüfen

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

Haematologica (Roma), 2022-05, Vol.107 (5), p.1086-1094

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.403-404

2022

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects

Clinical drug investigation, 2017-06, Vol.37 (6), p.571-579

2017

Link zum Volltext

Verfügbarkeit prüfen

Consideration of the proxy modelling validation framework

British Actuarial Journal, 2024-02, Vol.29

2024

Link zum Volltext

Verfügbarkeit prüfen

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans

Xenobiotica, 2019-04, Vol.49 (4), p.422-432

2019

Link zum Volltext

Verfügbarkeit prüfen

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

Leukemia & lymphoma, 2020-10, Vol.61 (12), p.2931-2938

2020

Link zum Volltext

Verfügbarkeit prüfen

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

Clinical pharmacokinetics, 2017-06, Vol.56 (6), p.661-669

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 381

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(363)
Mit Volltextzugriff
(353)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(262)
Life Sciences & Biomedicine
(197)
Humans
(139)
Male
(64)
Animals
(62)
Female
(60)
Physical Sciences
(41)
Mice
(38)
Middle Aged
(38)
Science & Technology - Other Topics
(37)
Adult
(34)
Oncology
(33)
Aged
(30)
Multidisciplinary Sciences
(29)
Technology
(29)
Covid-19
(28)
Pharmacology & Pharmacy
(25)
Life Sciences
(22)
Patients
(21)
Sars-Cov-2
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(14)
Nature
(13)
Plos One
(8)
Journal Of Clinical Oncology
(6)
Nature Communications
(6)
Journal Of Biopharmaceutical Statistics
(5)
Cancer Research
(4)
Molecular & Cellular Proteomics
(4)
Molecular Therapy. Oncolytics
(4)
Plant Physiology
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Intrusive social support among Black and White individuals with type 2 diabetes: A "Control issue" or a sign of "Concern and love"?

Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review

BEATS: Bayesian hybrid design with flexible sample size adaptation for time‐to‐event endpoints

Incorporating historical information to improve dose optimization design with toxicity and efficacy endpoints: iBOIN‐ET

Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior

A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling

Flexible seamless 2-in-1 design with sample size adaptation

Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies

Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience

Quantitative Translation in Immuno‐Oncology Research and Development

PMED: Optimal Bayesian Platform Trial Design with Multiple Endpoints

Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Flexible Bayesian subgroup analysis in early and confirmatory trials

Practical Considerations for Subgroups Quantification, Selection and Adaptive Enrichment in Confirmatory Trials

Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study

A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects

Consideration of the proxy modelling validation framework

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

Suchergebnisse filtern